Purpose: To evaluate the effect of a single intravitreal bevacizumab injection on visual acuity, contrast sensitivity and optical coherence tomographymea su red cen tral macular thickness in eyes with macular edema from branch re tinal vein occlusion. Methods: Seventeen eyes of 17 patients with macular edema from unilateral branch retinal vein occlusion were treated with a single bevacizumab injection. Patients were submitted to a complete evaluation including best corrected visual acuity, contrast sensitivity and optical coherence tomography measurements before treatment and one and three months after injection. Visual acuity, contrast sensitivity and optical coherence tomography measurements were compared to baseline values. Results: Mean visual acuity measurement improved from 0.77 logMAR at baseli ne to 0.613 logMAR one month after injection (P=0.0001) but worsened to 0.75 logMAR after three months. Contrast sensitivity test demonstrated significant improvement at spatial frequencies of 3, 6, 12 and 18 cycles/degree one month after injection and at the spatial frequency of 12 cycles/degree three months after treatment. Mean ± standard deviation baseline central macular thickness (552 ± 150 µm) reduced sig ni ficantly one month (322 ± 127 µm, P=0.0001) and three mo nths (439 ± 179 µm, P=0.01) after treatment. Conclusions: Bevacizumab injection improves visual acuity and contrast sensitiv i t y and reduces central macular thickness one month after treatment. Visual acuity returns to baseline levels at the 3month followup, but some beneficial effect of the treatment is still present at that time, as evidenced by optical coherence tomographymea sured central macular thickness and contrast sensitivity measurements.
INTRODUCTION
Branch retinal vein occlusion (BRVO) is a common retinal vascular disorder that can lead to significant visual loss, particularly when se con dary macular edema (ME) develops (1) . Although laser photocoagulation has been the only effective evi dencebased treatment for such patients, recent evidence supports the use of intravitreal pharmacotherapies as valid adjuncts or even as alternative treatments to standard laser photocoagulation (2) . Once a BRVO develops, retinal ischemia ensues downstream from the site of occlusion. Retinal ischemia and hypoxia are the most im por tant upregulators of vascular endothelial growth factor (VEGF) pro duction (3) , which constitutes one of the most potent permeabili zin g agents known and which has been implicated in the pathoge nesis of ME of various etiologies (4, 5) . Therefore, VEGF inhibition appears to be a promising treatment modality for ME (6) . In fact, recent studies have suggested a beneficial effect of intravitreous antiVEGF agents such as bevacizumab for the reduction of ME from different etiolo gies, including BRVO (710) . Some authors reported improvement in best corrected visual acuity (BCVA) at 1, 4, 8, and 12 weeks after just one intravitreal bevacizumab (IVB) injection; however, no significant improvement was noted after 24 weeks (11) . In 2007, a study reported that ME accompanied by BRVO recurred 2.1 months after injection
Single intravitreal bevacizumab injection effects on contrast sensitivity in macular edema from branch retinal vein occlusion
Efeito de uma única injeção intravítrea de bevacizumabe sobre a sensibilidade ao contraste no edema macular causado por oclusão de ramo venoso da retina intravitreal bevacizumab (IVB) injection (12) , while others reported that the effects disappeared after 6 weeks (2, 10) . In other study, eyes were treated with three initial IVB injections of 1.25 mg at monthly in ter vals. Subsequent retreatment was based on optical coherence tomography (OCT)measured central retinal thickness (13) . Most of the previous studies evaluating IVB injection in eyes with BRVO have based their conclusions on BCVA and central macular thi ckness (CMT) measurements on OCT. However, it is important to con sider that the use of other visionfunction tests may provide va lua ble additional information in order to further evaluate the effects of treat ment (1417) . Contrast sensitivity (CS) is one such test that provides a measure of the ability to see lowcontrast patterns, and it has been suggested that it can provide more information on visual function than BCVA (14, 18) . The strong associations between CS and functional abilities provide a rationale for including CS measurements in clinical trials (19) . It seems clear from the abovementioned studies that recurren ce of ME after initial successful treatment is very common, and many authors have suggested two to three injections over the first 56 months after vein occlusion (12, 20) . Other authors advise repeating IVB injection every time ME is present (21) , with frequencies of up to one injection every 6 weeks (22) at an increased risk of complications. Therefore, des pite the general belief that repeated IVB injections are needed for the treatment of ME from BRVO, there are several issues open to ques tioning regarding the use of IVB injection. The most important issue is that the exact duration of the effect of IVB injec tion in eyes with ME from BRVO is not clear, and therefore clearcut recommendations as to the frequency of IVB use are not available. Although patients may be given multiple injections, it is important to know what to ex pect of the first treatment an issue that has not been properly dealt with in previous studies in order to reasonably support a certain therapeutic regimen. The purpose of the present study is therefore to evaluate prospectively the effect of a single IVB injection on OCTestimated ME, BCVA and CS in patients with BRVO followed for 3 months.
METHODS
This was an interventional, prospective, consecutive study con duc ted between October 2008 and December 2009. The study followed the principles of the Declaration of Helsinki, approval from the Insti tutional Review Board Ethics Committee was obtained and all parti cipants gave their informed consent.
The study included 17 eyes of 17 patients (10 women) with a diag nosis of ME due to unilateral BRVO confirmed by OCT, fluorescein an giography and fundus photography. Patients were included in the study independent of the size of the area of leakage and time of occur rence of BRVO. Other inclusion criteria were CMT, as determined by OCT, greater than 300 µm, bestcorrected distance VA measure ment worse than 20/40 and absence of previous treatment over the last 3 months.
BCVA measurements were performed with the Early Treatment Diabetic Retinopathy Study (ETDRS) chart (Precision Vision, Aurora, Colo rado, USA). Contrast sensitivity was measured with the VCTS® 6500 (Vistech Consultants Incorporation, Dayton, OH, USA) in photopic con ditions (85 cd/m 2 ) that allows evaluation of 5 spatial frequen cies with sinewave grating charts ranging between 1.5 and 18 cycles/ degree (cpd). The patient should view the chart monocularly from a 10foot distance (or 3foot distance for low vision) with the best specta cle correction in place. The test proceeded from higher to lower contrast and from lower to higher spatial frequency. At each spatial fre quency, the target with the lowest contrast that was cor rectly iden tified before any preceding error was recorded as the CS for that frequency. The contrast threshold was measured from the last correct response. CS values, derived from the table provided in the Vistech manual, ranged from 3 to 260 and depended on the frequency. The CS levels in each row ranged from 0.47 to 2.23; 0.60 to 2.34; 0.70 to 2.41; 0.70 to 2.23; and 0.60 to 1.95 log units for 1.5, 3, 6, 12, and 18 cycles/degree, respectively.
Patients received one single intravitreal injection (1.25 µg/0.05 cc) of bevacizumab. VA, CS, fluorescein angiography and OCT were perfor med immediately prior to treatment and repeated at 1 and 3 months after injection. All injections were performed following international guidelines at operating room sterile drape, previous 5% topical po vidone (23) , and prophylactic topical antibiotics were given for 2 days before and 3 days postinjection.
Fluorescein angiograms were obtained after injection of 5 mL of 10% sodium fluorescein solution into the antecubital vein. The time for the dye to first appear in the arterioles until the end of the lami nar filling stage was recorded as the arterial venous filling time. The classification of BRVO was based on fluorescein angiographic criteria: ischemic lesions had 5 or more optic disc size areas of retinal nonper fusion while nonischemic occlusions had less than 5 such lesions.
Subjects underwent ocular imaging with dilated pupils using a commercially available, Stratus OCT (Carl Zeiss Meditec, Dublin, Cali fornia, USA). Quality assessment of Stratus OCT scans was evaluated by an experienced examiner. Goodquality scans had to have focused images and signal strength equal to or higher than 7 and radial scans centered on the fovea. The fast macular thickness protocol was used to obtain macular thickness measurements with the Stratus OCT. OCT measurements of the macula were generated from six 6 mm li near scans in a spokelike radial configuration with each line 30º apart. Macular thickness parameters were automatically calculated by the software (version 4.0.1) as the distance between the inner limiting membrane and retinal pigment epithelium.
Data regarding VA and CS were converted to logMAR before analy sis and calculations. The descriptive statistics included fre quen cy and mean value ± standard deviation (SD) for normally distri bu ted varia bles and median, first quartile and third quartile for nonnormally distributed variables. Analysis of histograms and the Kolmogorov Smir nov test were used to evaluate the normality assumption. We used the paired ttest for comparisons of normally distributed para meters and the Wilcoxon signedrank test for parameters that did not satisfy the normality assumption.
We calculated correlations using either Spearman's rank or Pear son's correlation coefficients. A P value of less than 0.05 was consi dered statistically significant. The statistical analyses were performed using the software SPSS v.15.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
A total of 17 intravitreal injections of bevacizumab were perfor med with no ocular or systemic adverse reactions noted. Seventeen patients completed the 1month followup period, and 13 patients com pleted the 3month followup period.
At baseline, none of the eyes had evidence of retinal or iris neo vascularization or elevated intraocular pressure. The mean age ± SD was 65.5 ± 12.1 years. The mean duration of symptoms ± SD before treatment was 29.0 ± 28.6 weeks (range 296 weeks). The majority of the cases presented the temporal inferior branch being the site of occlu sion in, 9 (53%) of the eyes. This data differed from the study alrea dy published (24) in which the majority of patients presented the superior branch as the main occlusion site.
The mean baseline VA of 17 affected eyes was 0.772 logMAR. After injection, 17 eyes had a 1month followup visit, which demonstrated an improvement in the mean VA to logMAR 0.613, (P=0.0001). Thir teen eyes had a 3month followup visit; the mean baseline VA was 0.75 logMAR and after 3 months of followup, 0.77 logMAR (P=0.139), demonstrating no statistical significance (Figure 1) .
The CS test demonstrated in photopic conditions statistical sig ni fi cance in all spatial frequencies of 1.5 (P=0.10), 3 (P=0.005), 6 (P=0.003), 12 (P=0.001) and 18 cycles/degree (P=0.007) at 4week followup. Statistical significance was observed after 3 months of treat ment in the high spatial frequency of 12 cycles/degree (P=0.034), between the thirteen eyes ( Statistically significant reductions in CMT by OCT were demons trated after a single bevacizumab injection at the 4week visit. Seven teen eyes had a 4week followup OCT; the mean CRT was 552.47 ± 150.36 µm at initial presentation and 322 ± 127 µm at the 4week visit (P=0.0001). Among the thirteen eyes at the 3month followup, the mean CMT was 570.77 ± 159.3 µm at initial presentation and 439 ± 179 µm at the 3month visit (P=0.01) (Figure 2) .
A statistically significant negative correlation was observed at the 3month followup between CMT measurements and CS at spatial frequencies of 1.5 (P=0.14), 3 (P=0.002), 6 (P=0.001), and 12 (P=0.002) cpd (Spearman's rank correlation test). A statistically significant posi tive correlation was observed between CMT measurements and bestcor rected VA measured at 1month (P=0.022) and 3month (P=0.025) followup (Pearson's correlation test).
DISCUSSION
Several studies support the hypothesis that VEGF inhibition has a beneficial effect in eyes with ME secondary to BRVO, at least in the short term (8, 1012, 2022) . Two small prospective case series (8, 12) showed sig nificant improvement in VA and OCTmeasured CMT one month after a single IVB injection. Our data also confirm such findings because a highly statistically significant improvement was observed, in VA and OCTmeasured CMT.
Nevertheless, the snellen VA test is a relatively crude index of vi sual function, until now it measures resolution only with high contrast targets, whereas objects in the real world exhibit varying degrees of contrast and a varying content of spatial frequencies (25) . This study measured CS and found improvement in 17 patients with ME from BRVO after a single IVB injection, between one and three months of follow up.
Considering middle (6 cycles/degree) and both high spatial fre quen cies (12 and 18 cycles/degree), patients with a history of less than 1 year demonstrated improvement in the middle and both high spatial frequencies when compared to patients with a history of more than 1 year that demonstrated improvement in the middle spatial fre quencies and among the highs, in the 12 and 18 cycles/degrees, only in the 12 th cycle/degree. Nevertheless, in the 3 months of followup, no statistical significance was found. This could be perhaps due to the small number of patients or due time of reporting the disease by the patient does not match with the true onset time of BRVO, since the majority of the patients with the disease could be asymptomatic (26) . In our study, the dose of 1.25 mg of bevacizumab was similar to several previous studies (8, 1013, 21, 22) using the same treatment modality ex cept for that used in the study published in 2007 which used 2.5 mg of bevacizumab with similar favorable results (20) . The favorable effect of treatment observed in our study is also in agreement with the po sitive results obtained by others authors which used repeated 2.0 mg bevacizumab injections at three months interval in patients with central and hemicentral retinal vein occlusion (27) . While it seems clear that IVB injection has a shortterm beneficial effect, it is also clear from several studies that recurrence of ME is rather frequent (8, 11, 12) , and very often repeated injections are neces sary in patients with retinal vein occlusion. The exact duration of the beneficial effect of a single IVB injection is still unknown, and very few studies have addressed this issue in a systematic way in patients with BRVO.
Studies evaluated retrospectively the effect of IVB injection in eyes with ME from BRVO. While in all studies reduction of ME was clear after a few weeks, multiple repeated injections were used in three of these studies (10, 12, 21) , making it difficult to evaluate the exact duration of the first treatment. On the other hand, the effect of a single IVB injection was evaluated retrospectively in 22 eyes with ME from BRVO and compared the effect of triamcinolone acetonide injection in 28 eyes. BCVA improved at 1, 4, 8 and 12 weeks but not at 24 weeks postinjection in the bevacizumab group (11) . Three prospective studies evaluated the role of bevacizumab injection after BRVO. The first evaluated 22 patients with BRVO who received 2.5 mg of IVB injection. The injections were repeated every 6 weeks when persistent or recurring ME was noted (20) . The second evaluated 12 patients with BRVO who received a single 1.25 mg beva cizumab injection and were followed for 3 months. Visual acuity and OCTmeasured CMT improved at 1 and 3 months after treatment (8) . The third evaluated the response of a single bevacizumab treatment in 7 eyes with BRVO. Improvement in VA reached a peak between 3 and 6 weeks after injection, while a decrease in VA was observed between weeks 6 and 9. The authors suggest that using OCT exami na tion between weeks 3 and 6 after the first treatment may be helpful in judging the appropriate time for reinjection (28) . The need of multiple repeat antiVEGF injections has also been recently emphasized by the Branch Retinal Vein Occlusion (BRAVO) study where patients were evaluated with monthly injections of Ranibizumab for 6 months. The study enrolled 397 patients and demonstrated great beneficial in central macular thickness measurements in the treated group over a sham group (29) . Our study is important because we have evaluated in a systema tic way the effect of a single IVB injection after one and three months, using not only VA and OCTmeasured CMT, but also careful CS func tion. The reason for the continuance of CS improvement after three months of followup even the VA did not demonstrate it could be be cause some eyes with reduced central vision may surprisingly show good contrast sensitivity, especially for gratings of low spatial frequencies (25) . CS is more closely associated with tasks requiring distance judg ment, night driving and mobility (15) . Patients with limitations in distin guishing contrast could have difficulties in several daytoday situa tions (14) . Because it is already known that the ability of an individual to realize the details of an object is determined mainly by how that person distinguishes contrast (30) , evaluating CS is extremely impor tant when assessing the effect of new treatment modalities. Because of this, considering both VA and CS when assessing the outcomes of clinical trials may provide a more complete picture of the effects of treatment on vision than either measure alone (19) . Our study indicated that a single IVB injection produces significant improvement in VA, CS and macular thickness measurements 4 weeks after injection, and the improvements regarding CS and macular thickness measurements last for at least 12 weeks, although VA did not differ when compared to preoperative evaluation. The optimum dosing and sequence for IVB injection in BRVO is still undetermined. While the exact number of injections necessary to maintain improved VA in cases of BRVO is unknown, our study indicates that improvement in CS and CMT is still present 3 months after a single IVB injection.
We acknowledge some shortcomings of our study, which include a relatively small number of patients, a lack of controls and a short followup. Nevertheless, clear evidence could be obtained that IVB in jection rapidly improved VA, CS and CMT in the shortterm followup, and the beneficial effects persisted after 3 months for CMT and CS. Multicenter clinical trials are necessary to prove the longterm effect of bevacizumab, as well as to determine the frequency of repeated injections for the treatment of ME due to BRVO.
